Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroVax with high-dose interleukin-2 in metastatic renal cell carcinoma
ISRCTN83977250Phase 2Completed
- Sponsor
- Oxford BioMedica
- Start
- Jan 2004
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MVA-5T4 and aldesleukin in renal cell carcinoma (RCC), sponsored by Oxford BioMedica. Primary endpoints: Safety and tolerability of TroVax and Immune responses induced by treatment. Started Jan 2004; status: completed.
02
Drugs
MVA-5T4aldesleukin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ISRCTN83977250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN83977250.